OncoMatch/Clinical Trials/NCT06414902

18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer

Is NCT06414902 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies ArabinoFuranosylGuanine [18F]F-AraG for esophageal cancer.

Phase 1RecruitingM.D. Anderson Cancer CenterNCT06414902Data as of May 2026

Treatment: ArabinoFuranosylGuanine [18F]F-AraG — To learn if 18F-FAraG PET scans can find tumors in participants with esophageal cancer and predict a participant's response to treatment.

Check if I qualify

Extracted eligibility criteria

Cancer type

Esophageal Carcinoma

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Kidney function

eGFR < 40 within 1 month prior to receiving 8F-FAraG [excluded]

eGFR<40 within 1 month prior to receiving 8F-FAraG

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

MD Anderson Cancer Center · Houston, Texas

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify